Shuttle Pharmaceuticals Holdings, Inc. Material Event - What Happened

Hey there! Let's break down what's going on with Shuttle Pharmaceuticals Holdings, Inc. in a way that makes sense, without all the confusing finance talk. Think of this as me explaining the news to you over a cup of coffee.

---

1. What happened? (The actual event, in plain English)

Shuttle Pharmaceuticals just announced that they've made an important change to an existing agreement where they're acquiring assets from another company. As part of this change, they issued 320,496 new shares of their common stock to the seller (1542770 BC Ltd.) as an accelerated payment. This stock payment covers a portion of what's called the "First Installment Payment" for the acquisition.

2. When did it happen?

This amendment became effective and the shares were issued on December 23, 2025. The company officially reported this news to the public on December 29, 2025. The original agreement to acquire the assets was made on November 20, 2025.

3. Why did it happen? (Context and background)

To understand why this event is happening, let's quickly look at the bigger picture. Shuttle Pharmaceuticals is a company focused on developing new treatments for cancer, especially those that work with radiation therapy.

This particular event is a direct result of an ongoing acquisition where Shuttle Pharma is buying assets from another company. These assets could be anything from new technologies, intellectual property, or other valuable resources that help Shuttle Pharma in its mission. The amendment specifically changed how a part of the first payment for these assets was made, opting to use company stock now rather than waiting or using a different payment method for that specific portion. This suggests a strategic decision to finalize part of the payment using their own equity.

4. Why does this matter? (Impact and significance)

Okay, so why should you care about this? This isn't just a small update; it could significantly change things for Shuttle Pharma.

• It's a step forward in an acquisition: This means Shuttle Pharma is actively growing or enhancing its capabilities by bringing in new assets. If these assets are valuable, they could strengthen the company's research pipeline or operational efficiency.
• It involves issuing new shares: When a company issues new shares, it means existing shareholders now own a slightly smaller percentage of the company. This is called "dilution." The 320,496 shares issued represent 19.99% of the company's outstanding shares as of the original agreement's closing date. While this dilutes existing ownership, the hope is that the value of the acquired assets will increase the overall company value, potentially offsetting this dilution.
• The shares were valued: For this transaction, the shares were valued at $1.76 each. This gives us a benchmark for how the company and seller valued this portion of the payment.

Basically, this event affects the company's future prospects by adding new assets and impacts its financial structure through the issuance of new stock.

5. Who is affected? (Employees, customers, investors, etc.)

A few different groups of people will feel the ripple effect of this news:

• The Company (Shuttle Pharma itself): They are successfully moving forward with an acquisition, which could mean new opportunities and a stronger position in the market. They've also used their stock as currency for this deal.
• Their Employees: Depending on the nature of the acquired assets, this could mean exciting new projects or expanded teams.
• Patients/Customers: If the acquired assets are related to new treatments or technologies, this could eventually lead to new or improved therapies for patients.
• Investors/Shareholders: This is probably you! Your ownership percentage in the company has been slightly diluted by the issuance of these new shares. The overall impact on your investment will depend on how valuable the acquired assets turn out to be and how the market reacts to the dilution versus the strategic benefit of the acquisition.

6. What happens next? (Immediate and future implications)

So, what's on the horizon?

• In the short term: The immediate transaction of issuing shares is complete. We might see some market reaction to the dilution and the news of the acquisition.
• Looking further ahead: Shuttle Pharma will continue with the acquisition process. The remaining portion of the "First Installment Payment" will be made in cash, as originally agreed. Investors will want to watch for more details about what specific assets were acquired and how they plan to integrate them into their operations and research. This will give a clearer picture of the long-term benefits of this deal.

7. What should investors/traders know? (Practical takeaways)

Alright, for those of you watching your portfolios or thinking about buying/selling:

• Understand the dilution: Be aware that new shares were issued, which means your existing shares represent a slightly smaller piece of the company.
• Focus on the acquisition's value: This share issuance is part of a larger acquisition. The real long-term impact depends on the strategic value and potential of the assets Shuttle Pharma is acquiring. Is it a good deal for the company?
• Note the valuation: The shares were valued at $1.76 for this specific transaction. You might want to compare this to the current market price of SHPH stock.
• Keep an eye on: Any follow-up announcements from the company regarding the specifics of the acquired assets and how they fit into Shuttle Pharma's future plans. This will be key to understanding the full picture.
• Consider your risk: Biotech stocks can be volatile. While an acquisition can be positive, the dilution is a factor to consider in your overall investment strategy.